
|Videos|May 7, 2021
Focusing on 24-month data of the PALADIN study
Author(s)OTE Staff Reports, David Hutton
Dr Michael A. Singer speaks on the highlights of his presentation focusing on IOP in the PALADIN 24-month data intravitreal steroid (ILUVIEN).
Advertisement
Dr Michael A. Singer of the Medical Center Ophthalmology Associates in San Antonio, Texas, speaks on the highlights of his presentation focusing on intraocular pressure (IOP) in the PALADIN 24-month data intravitreal steroid (ILUVIEN), presented during ARVO 2021.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
SubscribeAdvertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA grants RMAT designation to Emmecell's EO2002 for corneal endothelial disease
2
Opus Genetics reaches FDA alignment on phase 3 registrational design for OPGx-LCA5 gene therapy
3
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
4
Port Delivery System Therapies in Retinal Vascular Diseases
5






















